Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	1.10B +38.5%
Revenue (ttm)	291.85M +43.7%
Net Income	554,000
EPS	0.00
Shares Out	172.43M
PE Ratio	1,986.28
Forward PE	61.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,246,142
Open	6.26
Previous Close	6.12
Day's Range	6.17 - 6.41
52-Week Range	3.95 - 10.08
Beta	0.99
Analysts	Buy
Price Target	10.83 (+70.02%)
Earnings Date	May 7, 2026

About XERS

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 435
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS
• Website: https://www.xerispharma.com

Analyst Summary

According to 6 analysts, the average rating for XERS stock is "Buy." The 12-month stock price target is $10.83, which is an increase of 70.02% from the latest price.

Price Target

$10.83

(70.02% upside)

Analyst Consensus: Buy